Skip to main content

Calcifediol Pregnancy and Breastfeeding Warnings

Brand names: Calderol, Rayaldee

Medically reviewed by Last updated on Feb 11, 2022.

Calcifediol Pregnancy Warnings

Calcifediol has been assigned to pregnancy category C. Calcifediol has been shown to be teratogenic, resulting in external and skeletal abnormalities, when used at doses of 6 to 12 times the dose recommended for human use. There are no controlled data in human pregnancy. Calcifediol should only be used during pregnancy when benefit outweighs the risk.

Earlier literature expressed concerns over the development of supravalvular aortic stenosis, craniofacial abnormalities, and dental abnormalities in infants and children with idiopathic hypercalcemia. Whether or not prenatal factors predisposed these children to the development of hypercalcemia is not known.

Fifteen hypoparathyroid women receiving 50,000 to 250,000 Intl units of vitamin D2 experienced 27 uneventful births. No cardiovascular or craniofacial abnormalities were reported.

See references

Calcifediol Breastfeeding Warnings

There are no data on the excretion of calcifediol into human milk.

See references

References for pregnancy information

  1. Rowe RD, Cooke RE. Vitamin D and craniofacial and dental anomalies of supravalvular stenosis. Pediatrics. 1969;43:1-2.
  2. Taussig HB. Possible injury to the cardiovascular system from vitamin D. Ann Intern Med. 1966;65:1195-200.
  3. Goodenday LS, Gordon GS. No risk from vitamin D in pregnancy. Ann Intern Med. 1971;75:807-8.
  4. Product Information. Calderol (calcifediol). Organon. 2001.

References for breastfeeding information

  1. Product Information. Calderol (calcifediol). Organon. 2001.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.